Literature DB >> 22543575

What's in a name? What constitutes the clinical diagnosis of osteoporosis?

E S Siris1, S Boonen, P J Mitchell, J Bilezikian, S Silverman.   

Abstract

Osteoporosis is a skeletal disorder in which reductions in bone strength predispose to an increased risk for fractures. Currently, the diagnosis is officially made based exclusively on bone mineral density T-scores that are ≤-2.5 at the spine or hip. Limiting the clinical diagnosis of osteoporosis solely to a T-score-based criterion, which is the official convention in the USA, creates uncertainty about the use of the term osteoporosis to diagnose older women and men who have T-scores >-2.5, but either have already sustained low-trauma fractures or are recognized as having high fracture risk based on absolute fracture risk calculations from FRAX or other algorithms. A failure to diagnose such patients as having osteoporosis may be one component of the well-documented underdiagnosis and undertreatment of this disease which limits our ability to reduce the burden of fractures worldwide. There is a need to expand the criteria for making a clinical diagnosis and to codify these changes in order to help patients, physicians, policy makers, and payers better understand who has this disease and the elevated risk for fracture that it represents.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22543575     DOI: 10.1007/s00198-012-1991-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  22 in total

1.  Hip fracture in women without osteoporosis.

Authors:  Stacey A Wainwright; Lynn M Marshall; Kristine E Ensrud; Jane A Cauley; Dennis M Black; Teresa A Hillier; Marc C Hochberg; Molly T Vogt; Eric S Orwoll
Journal:  J Clin Endocrinol Metab       Date:  2005-02-22       Impact factor: 5.958

Review 2.  Coordinator-based systems for secondary prevention in fragility fracture patients.

Authors:  D Marsh; K Akesson; D E Beaton; E R Bogoch; S Boonen; M-L Brandi; A R McLellan; P J Mitchell; J E M Sale; D A Wahl
Journal:  Osteoporos Int       Date:  2011-05-24       Impact factor: 4.507

3.  The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008.

Authors:  B Dawson-Hughes; A C Looker; A N A Tosteson; H Johansson; J A Kanis; L J Melton
Journal:  Osteoporos Int       Date:  2011-06-30       Impact factor: 4.507

4.  Risk of new vertebral fracture in the year following a fracture.

Authors:  R Lindsay; S L Silverman; C Cooper; D A Hanley; I Barton; S B Broy; A Licata; L Benhamou; P Geusens; K Flowers; H Stracke; E Seeman
Journal:  JAMA       Date:  2001-01-17       Impact factor: 56.272

5.  Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial.

Authors:  Meghan G Donaldson; Lisa Palermo; Kristine E Ensrud; Marc C Hochberg; John T Schousboe; Steven R Cummings
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

6.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

7.  Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial.

Authors:  John A Kanis; Olof Johnell; Dennis M Black; Robert W Downs; Somnath Sarkar; Thomas Fuerst; Roberta J Secrest; Imre Pavo
Journal:  Bone       Date:  2003-09       Impact factor: 4.398

8.  Bone mineral density thresholds for pharmacological intervention to prevent fractures.

Authors:  Ethel S Siris; Ya-Ting Chen; Thomas A Abbott; Elizabeth Barrett-Connor; Paul D Miller; Lois E Wehren; Marc L Berger
Journal:  Arch Intern Med       Date:  2004-05-24

9.  Prior fractures are common in patients with subsequent hip fractures.

Authors:  Beatrice J Edwards; Andrew D Bunta; Christine Simonelli; Mark Bolander; Lorraine A Fitzpatrick
Journal:  Clin Orthop Relat Res       Date:  2007-08       Impact factor: 4.176

10.  Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women.

Authors:  Stephen Gehlbach; Kenneth G Saag; Jonathan D Adachi; Fred H Hooven; Julie Flahive; Steven Boonen; Roland D Chapurlat; Juliet E Compston; Cyrus Cooper; Adolfo Díez-Perez; Susan L Greenspan; Andrea Z LaCroix; J Coen Netelenbos; Johannes Pfeilschifter; Maurizio Rossini; Christian Roux; Philip N Sambrook; Stuart Silverman; Ethel S Siris; Nelson B Watts; Robert Lindsay
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

View more
  16 in total

1.  The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study.

Authors:  C Cipriani; J Pepe; F Bertoldo; G Bianchi; F P Cantatore; A Corrado; M Di Stefano; B Frediani; D Gatti; A Giustina; T Porcelli; G Isaia; M Rossini; L Nieddu; S Minisola; G Girasole; M Pedrazzoni
Journal:  J Endocrinol Invest       Date:  2017-09-27       Impact factor: 4.256

Review 2.  Osteoporosis diagnosis in men: the T-score controversy revisited.

Authors:  Neil Binkley; Robert Adler; John P Bilezikian
Journal:  Curr Osteoporos Rep       Date:  2014-12       Impact factor: 5.096

3.  National Bone Health Alliance: an innovative public-private partnership improving America's bone health.

Authors:  David B Lee; Mia Rochelle Lowden; Valerie Patmintra; Katie Stevenson
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

Review 4.  Treatment of osteoporosis after alendronate or risedronate.

Authors:  P Eiken; P Vestergaard
Journal:  Osteoporos Int       Date:  2015-10-05       Impact factor: 4.507

Review 5.  Interaction between bone and muscle in older persons with mobility limitations.

Authors:  L Ferrucci; M Baroni; A Ranchelli; F Lauretani; M Maggio; P Mecocci; C Ruggiero
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 6.  What's in a name revisited: should osteoporosis and sarcopenia be considered components of "dysmobility syndrome?".

Authors:  N Binkley; D Krueger; B Buehring
Journal:  Osteoporos Int       Date:  2013-08-01       Impact factor: 4.507

7.  Clinical management of osteoporotic vertebral fracture treated with percutaneous vertebroplasty.

Authors:  Anna Capozzi; Giovanni Scambia; Alessandro Pedicelli; Maurizio Evangelista; Roberto Sorge; Stefano Lello
Journal:  Clin Cases Miner Bone Metab       Date:  2017-10-25

8.  Estimation of 10-year probability bone fracture in a selected sample of Palestinian people using fracture risk assessment tool.

Authors:  Mai B Aker; Adham S Abu Taha; Sa'ed H Zyoud; Ansam F Sawalha; Samah W Al-Jabi; Waleed M Sweileh
Journal:  BMC Musculoskelet Disord       Date:  2013-10-05       Impact factor: 2.362

9.  Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway.

Authors:  M Hoff; S Skurtveit; H E Meyer; A Langhammer; A J Søgaard; U Syversen; E Skovlund; B Abrahamsen; S Forsmo; B Schei
Journal:  Osteoporos Int       Date:  2018-05-17       Impact factor: 4.507

Review 10.  Osteoporotic ankle fractures: A narrative review of management options.

Authors:  Mandeep S Dhillon; Rajesh Kumar Rajnish; Sandeep Patel; Devendra K Chouhan; Tungish Bansal
Journal:  J Clin Orthop Trauma       Date:  2019-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.